SCHEMBL5876984

SCHEMBL5876984

Cc1ccc(S(=O)(=O)n2nc(NC3CC3)c3c2CC(c2ccccc2)(c2ccc(F)cc2)C=C3)cc1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GPR6 P46095 2/20 0.35
KMT2A Q03164 3/20 0.34
MEN1 O00255 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
ALDH1A1 P00352 2/20 0.34
STAT1 P42224 1/20 0.34
NR1H2 P55055 1/20 0.33
NR1H3 Q13133 1/20 0.33
LMNA P02545 2/20 0.32
MAPT P10636 2/20 0.32
POLB P06746 1/20 0.32
GAA P10253 1/20 0.32
HTT P42858 1/20 0.32
TP53 P04637 1/20 0.32
CYP2C19 P33261 1/20 0.32
NPY5R Q15761 1/20 0.32
USP2 O75604 1/20 0.32
MAPK1 P28482 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5876201 0.97 USP2 (0.34) GPR6KMT2AMEN1SMN1; SMN2ALDH1A1
SCHEMBL5876040 0.96 KMT2A (0.36) GPR6KMT2AMEN1SMN1; SMN2LMNA
SCHEMBL5876012 0.95 NR1H2 (0.36) GPR6KMT2AMEN1ALDH1A1NR1H2
SCHEMBL5876672 0.93 KMT2A (0.35) KMT2AMEN1SMN1; SMN2ALDH1A1LMNA
SCHEMBL5877322 0.93 GPR6 (0.36) GPR6KMT2AMEN1ALDH1A1NR1H2
SCHEMBL5876606 0.92 KMT2A (0.34) GPR6KMT2AMEN1ALDH1A1NR1H2
SCHEMBL5876198 0.91 USP2 (0.37) KMT2AMEN1ALDH1A1NR1H2NR1H3
SCHEMBL5876220 0.90 NR1H2 (0.34) GPR6KMT2AMEN1ALDH1A1NR1H2
SCHEMBL5876491 0.90 ALDH1A1 (0.39) GPR6KMT2AMEN1SMN1; SMN2ALDH1A1
SCHEMBL5876144 0.90 CCR6 (0.42) KMT2AMEN1ALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7119115-B2 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2006-10-10 US disclosed
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2004-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology IDO1, IDO2, INMT GPR6 986/4885KMT2A 2326/4885MEN1 548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.